Nav: Home

New, more effective strategy for producing flu vaccines

December 05, 2016

MADISON, Wis. -- A team of researchers led by Yoshihiro Kawaoka, professor of pathobiological sciences at the University of Wisconsin-Madison School of Veterinary Medicine, has developed technology that could improve the production of vaccines that protect people from influenza B.

That technology is an influenza B vaccine virus "backbone" that would allow producers to grow vaccine viruses at high yield in mammalian cell culture rather than in eggs. Using the backbone as a template to add vaccine-virus-specific components, it would offer protection against both lineages of influenza B that circulate in the human population.

"We want to provide a system that produces influenza vaccines that are more efficacious," says Kawaoka. "It is better to produce influenza viruses for vaccine production in cells instead of eggs, but the problem is that influenza virus does not grow well in cell culture compared with embryonated eggs."

The new technology may overcome that challenge. The team published its results Monday, Dec. 5, in the Proceedings of the National Academy of Sciences.

Each year, the U.S. Food and Drug Administration, in collaboration with the Centers for Disease Control and Prevention and the World Health Organization, decides which strains of influenza virus to include in the seasonal flu vaccine. It typically includes two influenza A strains and two influenza B strains.

Growing vaccine viruses in high-yield cell culture should improve the ability of seasonal vaccines to protect against influenza A and B because vaccine viruses grown in mammalian cell culture are less likely to mutate compared to those grown in eggs. Mutations can lead to vaccine viruses that no longer match the intended strains of influenza.

"It may still not be perfect, but it will at least be substantially better than current vaccines," says Kawaoka, who notes no one else has successfully tried to produce high-yield influenza B vaccine virus before now. Last year, his research team created a high-yield influenza A vaccine virus candidate for cell culture production.

Per the CDC, growing vaccine viruses in high-yield cell culture may also enable faster and potentially greater production of vaccine. This could improve the ability of health officials to respond during an influenza pandemic.

To develop the influenza B vaccine virus backbone, Kawaoka's team screened influenza B viruses for random genetic mutations that led to improved replication.

Using these mutants as templates, the researchers attached the genes that code for the surface proteins that trigger the human immune response (and thus offer protection in vaccinated individuals) -- HA (hemagglutinin) and NA (neuraminidase). They selected the combinations of backbone mutations that supported better growth in cell culture, identifying two candidate backbones that led to higher amounts of vaccine virus.

The team identified the characteristics of each backbone that contributed to their improved yield and also found the backbones to be genetically stable. However, Kawaoka points out that more testing is required to discern whether they would increase vaccine virus yield under industrial conditions.

Several companies and federal agencies have already contacted him about the influenza A and influenza B backbones, Kawaoka says, and he is hopeful the systems can be adopted by vaccine manufacturers and grown in cell culture facilities already available in the United States and Japan.

Kawaoka's goal is to help develop more effective vaccines to protect people from influenza infection. According to the CDC, influenza sickens millions, hospitalizes hundreds of thousands, and kills tens of thousands of people each year in the U.S.

"This is something we have to do," Kawaoka says.

Kawaoka credits the Wisconsin Alumni Research Foundation for the support to complete this work. "Without that, we couldn't get it going," he says.
-end-
In addition to WARF, the current study was funded by the National Institute of Allergy and Infectious Diseases, Center for Research on Influenza Pathogenesis; Scientific Research on Innovative Areas from the Ministry of Education, Culture, Sports, Science and Technology of Japan; the Strategic Basic Research Program of the Japan Science and Technology Agency; and the Leading Advanced Projects for Medical Innovation from the Japan Agency for Medical Research and Development.

--Kelly April Tyrrell, kelly.tyrrell@wisc.edu, 608-262-9772

CONTACT: Yoshihiro Kawaoka, yoshihiro.kawaoka@wisc.edu (email only); or Kelly Tyrrell, University Communications, (608) 262-9772, kelly.tyrrell@wisc.edu

DOWNLOAD IMAGES: https://uwmadison.box.com/v/influenza

University of Wisconsin-Madison

Related Influenza Articles:

Birds become immune to influenza
An influenza infection in birds gives a good protection against other subtypes of the virus, like a natural vaccination, according to a new study.
Researchers shed new light on influenza detection
Notre Dame Researchers have discovered a way to make influenza visible to the naked eye, by engineering dye molecules to target a specific enzyme of the virus.
Maternal vaccination again influenza associated with protection for infants
How long does the protection from a mother's immunization against influenza during pregnancy last for infants after they are born?
Influenza in the tropics shows variable seasonality
Whilst countries in the tropics and subtropics exhibit diverse patterns of seasonal flu activity, they can be grouped into eight geographical zones to optimise vaccine formulation and delivery timing, according to a study published April 27, 2016 in the open-access journal PLOS ONE.
Influenza viruses can hide from the immune system
Influenza is able to mask itself, so that the virus is not initially detected by our immune system.
Using 'big data' to combat influenza
Team of scientists from the Icahn School of Medicine at Mount Sinai and Sanford Burnham Prebys Medical Discovery Institute among those who combined large genomic and proteomic datasets to identify novel host targets to treat flu.
Rapidly assessing the next influenza pandemic
Influenza pandemics are potentially the most serious natural catastrophes that affect the human population.
Early detection of highly pathogenic influenza viruses
Lack of appropriate drugs and vaccines during the influenza A virus pandemic in 2009, the recent Ebola epidemic in West Africa, as well as the ongoing Middle Eastern Respiratory Syndrome-Coronavirus outbreak demonstrates that the world is only insufficiently prepared for global attacks of emerging infectious diseases and that the handling of such threats remains a great challenge.
Study maps travel of H7 influenza genes
In a new bioinformatics analysis of the H7N9 influenza virus that has recently infected humans in China, researchers trace the separate phylogenetic histories of the virus's genes, giving a frightening new picture of viruses where the genes are traveling independently in the environment, across large geographic distances and between species, to form 'a new constellation of genes -- a new disease, based not only on H7, but other strains of influenza.'
Influenza A potentiates pneumococcal co-infection: New details emerge
Influenza infection can enhance the ability of the bacterium Streptococcus pneumoniae to cause ear and throat infections, according to research published ahead of print in the journal Infection and Immunity.

Related Influenza Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Climate Crisis
There's no greater threat to humanity than climate change. What can we do to stop the worst consequences? This hour, TED speakers explore how we can save our planet and whether we can do it in time. Guests include climate activist Greta Thunberg, chemical engineer Jennifer Wilcox, research scientist Sean Davis, food innovator Bruce Friedrich, and psychologist Per Espen Stoknes.
Now Playing: Science for the People

#527 Honey I CRISPR'd the Kids
This week we're coming to you from Awesome Con in Washington, D.C. There, host Bethany Brookshire led a panel of three amazing guests to talk about the promise and perils of CRISPR, and what happens now that CRISPR babies have (maybe?) been born. Featuring science writer Tina Saey, molecular biologist Anne Simon, and bioethicist Alan Regenberg. A Nobel Prize winner argues banning CRISPR babies won’t work Geneticists push for a 5-year global ban on gene-edited babies A CRISPR spin-off causes unintended typos in DNA News of the first gene-edited babies ignited a firestorm The researcher who created CRISPR twins defends...